EBSAM
CRL icon

Eubel Brady & Suttman Asset Management’s Charles River Laboratories CRL Stock Holding History

Eubel Brady & Suttman Asset Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-245
Closed -$71K – 124
2021
Q2 		$71K Buy
+245
New +$81.8K 0.01% 295

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Eubel Brady & Suttman Asset Management's CRL Position: Q3 2021 in Review

Eubel Brady & Suttman Asset Management sold out of Charles River Laboratories (CRL) in Q3 2021, closing a stake of 245 shares — an estimated $71K sold.

Eubel Brady & Suttman Asset Management first reported a position in CRL in Q2 2021 and held it in 1 quarter. The position peaked at $71K in Q2 2021. 676 funds tracked by Wall St. Rank hold CRL as of Q3 2021.

  • Eubel Brady & Suttman Asset Management reported no remaining Charles River Laboratories position as of Q3 2021 after selling out during the quarter.
  • Eubel Brady & Suttman Asset Management sold 245 Charles River Laboratories shares in Q3 2021, an estimated $71K.
  • Eubel Brady & Suttman Asset Management first reported a position in Charles River Laboratories in Q2 2021 and held it in 1 quarter.
  • Eubel Brady & Suttman Asset Management's Charles River Laboratories position peaked at $71K in Q2 2021.
  • 676 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2021.

Based on Eubel Brady & Suttman Asset Management's 13F filing for Q3 2021, filed 5 Nov 2021.